In an update on its NATiV3 clinical program evaluating lanifibranor in MASH/NASH, Inventiva claims 'good progress in the recruitment of its Phase III clinical trial' and notes 'strong commitment from clinical trial sites'.

The company also says it is encouraged by the patient characteristics observed in the main NATiV3 cohort compared with those in its Phase IIb trial, and especially by a plateau effect observed in the weight gain curve.

In addition, Inventiva points out that its patent portfolio has been strengthened with a new patent obtained protecting the compound until 2043, and that it is currently working to find financing to ensure the continuity of its activities.

Copyright (c) 2024 CercleFinance.com. All rights reserved.